A 2-year follow-up to a randomized controlled trial on resistance training in postmenopausal women: vasomotor symptoms, quality of life and cardiovascular risk markers.

Sigrid Nilsson, Moa Henriksson, Mats Hammar, Emilia Berin, Sofia Sederholm Lawesson, Liam J Ward, Wei Li, Anna-Clara Spetz Holm
Author Information
  1. Sigrid Nilsson: Department of Obstetrics and Gynecology in Linköping, and Department of Biomedical and Clinical Sciences, Linköping University, 58185, Linköping, Sweden. sigrid.nilsson@liu.se.
  2. Moa Henriksson: Department of Obstetrics and Gynecology in Linköping, and Department of Biomedical and Clinical Sciences, Linköping University, 58185, Linköping, Sweden.
  3. Mats Hammar: Department of Obstetrics and Gynecology in Linköping, and Department of Biomedical and Clinical Sciences, Linköping University, 58185, Linköping, Sweden.
  4. Emilia Berin: Department of Obstetrics and Gynecology in Linköping, and Department of Biomedical and Clinical Sciences, Linköping University, 58185, Linköping, Sweden.
  5. Sofia Sederholm Lawesson: Department of Cardiology, and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
  6. Liam J Ward: Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Linköping University, Linköping, Sweden.
  7. Wei Li: Department of Obstetrics and Gynecology in Linköping, and Department of Biomedical and Clinical Sciences, Linköping University, 58185, Linköping, Sweden.
  8. Anna-Clara Spetz Holm: Department of Obstetrics and Gynecology in Linköping, and Department of Biomedical and Clinical Sciences, Linköping University, 58185, Linköping, Sweden.

Abstract

BACKGROUND: Most women experience vasomotor symptoms (VMS) during the menopausal transition. A 15-week resistance training intervention (RTI) significantly reduced moderate-to-severe VMS (MS-VMS) and improved health-related quality of life (HRQoL) and cardiovascular risk markers in postmenopausal women. Whether a short RTI could have long-term effects is unknown. We aimed to investigate whether there were intervention-dependent effects two years after a 15-week RTI on MS-VMS frequency, HRQoL, and cardiovascular risk markers in postmenopausal women.
METHODS: This observational prospective cohort study is a follow-up to a randomized controlled trial (RCT) on a 15-week RTI in postmenopausal women (n = 57). The control group had unchanged low physical activity during these first 15 weeks. At the follow-up contact two years post-intervention, 35 women agreed to participate in an additional physical visit at the clinic with clinical testing, blood sampling, and magnetic resonance imaging, identical to the protocol at the baseline visit at the start of the RCT.
RESULTS: Although all women showed reduced MS-VMS and increased moderate-to-vigorous physical activity (MVPA) over the 2-year follow-up compared to baseline, the groups from the original RCT (intervention group; IG, control group; CG) changed differently over time (p < 0.001 and p = 0.006, respectively) regarding MS-VMS. The IG maintained a significantly lower MS-VMS frequency than the CG at the 6-month follow-up. At the 2-year follow-up, there was no significant difference between the original RCT groups. No significant changes over time or differences between groups were found in HRQoL or cardiovascular risk markers. However, significant interactions between original RCT groups and time were found for visceral adipose tissue (p = 0.041), ferritin (p = 0.045), and testosterone (p = 0.010).
CONCLUSIONS: A 15-week resistance training intervention reduced MS-VMS frequency up to six months post-intervention compared to a CG, but the effect was not maintained after two years. The RTI did neither contribute to preserved improvements of cardiovascular risk markers nor improved HRQoL after two years compared to a CG.
TRIAL REGISTRATION: Clinical trials.gov registered ID: NCT01987778, trial registration date 2013-11-19.

Keywords

Associated Data

ClinicalTrials.gov | NCT01987778

References

  1. BMJ Open. 2020 May 5;10(5):e034541 [PMID: 32371512]
  2. J Am Heart Assoc. 2021 Feb 2;10(3):e017416 [PMID: 33470142]
  3. Menopause. 2012 Jun;19(6):691-6 [PMID: 22334056]
  4. Nat Rev Endocrinol. 2020 Mar;16(3):177-189 [PMID: 32020062]
  5. Med Sci Sports Exerc. 2003 Aug;35(8):1381-95 [PMID: 12900694]
  6. Biomed Res Int. 2014;2014:757461 [PMID: 24734243]
  7. Climacteric. 2022 Jun;25(3):264-270 [PMID: 34240669]
  8. Cochrane Database Syst Rev. 2014 Nov 28;(11):CD006108 [PMID: 25431132]
  9. Sci Rep. 2020 Nov 16;10(1):19837 [PMID: 33199796]
  10. PLoS One. 2016 Jun 17;11(6):e0157417 [PMID: 27315068]
  11. Lancet. 2008 Mar 1;371(9614):760-70 [PMID: 18313505]
  12. Health Qual Life Outcomes. 2003 Sep 10;1:41 [PMID: 14521718]
  13. Maturitas. 2016 Jun;88:84-9 [PMID: 27105704]
  14. Climacteric. 2013 Aug;16(4):438-46 [PMID: 23347190]
  15. Sci Rep. 2020 Mar 2;10(1):3838 [PMID: 32123242]
  16. Acta Obstet Gynecol Scand. 1993 Nov;72(8):648-55 [PMID: 8259753]
  17. Int J Environ Res Public Health. 2020 Sep 26;17(19): [PMID: 32993147]
  18. Climacteric. 2022 Dec;25(6):552-561 [PMID: 35904028]
  19. Maturitas. 2015 Jul;81(3):353-61 [PMID: 26022385]
  20. Maturitas. 2023 Oct;176:107794 [PMID: 37421844]
  21. J Clin Endocrinol Metab. 2004 Aug;89(8):3907-13 [PMID: 15292326]
  22. Obstet Gynecol Clin North Am. 2011 Sep;38(3):489-501 [PMID: 21961716]
  23. PLoS One. 2018 Feb 7;13(2):e0192495 [PMID: 29415060]
  24. Med Sci Sports Exerc. 2009 Mar;41(3):687-708 [PMID: 19204579]
  25. Maturitas. 2016 Mar;85:96-103 [PMID: 26857887]
  26. Maturitas. 2019 Aug;126:55-60 [PMID: 31239119]
  27. Circulation. 2008 Sep 16;118(12):1234-40 [PMID: 18765392]
  28. Menopause. 2022 May 01;29(5):537-544 [PMID: 35102099]
  29. Menopause. 2019 Nov;26(11):1327-1333 [PMID: 31567869]
  30. BJOG. 2015 Mar;122(4):565-75 [PMID: 25516405]

Grants

  1. 2014-2781/Vetenskapsrådet
  2. 2014-2781/Vetenskapsrådet
  3. 2014-2781/Vetenskapsrådet
  4. 2014-2781/Vetenskapsrådet
  5. 2014-2781/Vetenskapsrådet

MeSH Term

Humans
Female
Resistance Training
Quality of Life
Postmenopause
Middle Aged
Follow-Up Studies
Prospective Studies
Cardiovascular Diseases
Heart Disease Risk Factors
Hot Flashes
Vasomotor System
Exercise
Biomarkers

Chemicals

Biomarkers

Word Cloud

Created with Highcharts 10.0.0womenMS-VMSriskmarkersfollow-upRTIcardiovascularRCT15-weekHRQoLpostmenopausaltwoyearsgroupsCGp = 0symptomsresistancetraininginterventionreducedqualityfrequencytrialgroupphysicalactivity2-yearcomparedoriginaltimesignificantvasomotorVMSsignificantlyimprovedeffectsrandomizedcontrolledcontrolpost-interventionvisitbaselineIGmaintainedfoundlifeBACKGROUND:experiencemenopausaltransitionmoderate-to-severehealth-relatedlife Whethershortlong-termunknownaimedinvestigatewhetherintervention-dependentMETHODS:observationalprospectivecohortstudyn = 57unchangedlowfirst15 weekscontact35agreedparticipateadditionalclinicclinicaltestingbloodsamplingmagneticresonanceimagingidenticalprotocolstartRESULTS:Althoughshowedincreasedmoderate-to-vigorousMVPAchangeddifferentlyp < 0001006respectivelyregardinglower6-monthdifferencechangesdifferencesHoweverinteractionsvisceraladiposetissue041ferritin045testosterone010CONCLUSIONS:sixmonthseffectneithercontributepreservedimprovementsTRIALREGISTRATION:ClinicaltrialsgovregisteredID:NCT01987778registrationdate2013-11-19women:CardiovascularFollow-upHealth-relatedHotflushesMenopauseMidlifePhysicalVasomotor

Similar Articles

Cited By